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ABSTRACT 
OBJECTIVE(S): A dilated main pancreatic duct in the distal remnant after proximal-
pancreatectomy for IPMN poses a diagnostic dilemma. We sought to determine parameters 
predictive of remnant main-duct IPMN and malignancy during surveillance. 
METHODS: 317 patients underwent proximal-pancreatectomy for IPMN (Indiana University 
1991-2016). Main-duct dilation included those >5mm or “dilated” on radiographic reports. 
Statistics compared groups using Student’s T/Mann-Whitney U-tests for continuous variables, or 
Chi-Square/Fisher’s Exact test for categorical variables with P<0.05 considered significant. 
RESULTS:  High-Grade/Invasive-IPMN or adenocarcinoma at proximal-pancreatectomy 
predicted malignant outcomes (100.0% malignant outcomes; P<0.001) in remnant surveillance. 
Low/Moderate-Grade lesions revealed benign outcomes at last surveillance regardless of duct 
diameter. Twenty of 21 patients undergoing distal remnant re-operation had a dilated main-duct. 
Seven had main-duct IPMN on remnant pathology; these patients had greater mean maximum 
main-duct diameter prior to re-operation (9.5 vs 6.2mm, P=0.072) but this did not reach 
statistical significance. Several features showed high sensitivity/specificity for remnant main-
duct IPMN. 
CONCLUSIONS: Remnant main-duct dilation after proximal-pancreatectomy for IPMN 
remains a diagnostic dilemma. Several parameters show promise in accurately diagnosing main-
duct IPMN in the remnant. 
KEYWORDS: Pancreatic Duct, Pancreatic Neoplasms, Mucinous Neoplasms, Pancreatic Cyst, 
Pancreaticoduodenectomy 
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INTRODUCTION 
 Since the first description in 1982,[1] intraductal papillary mucinous neoplasms (IPMN) 
have become increasingly recognized as one of the most common cystic lesions of the 
pancreas.[2] Because of the variable risk of malignant transformation, the International 
Consensus guidelines were developed to aid clinicians in deciding which patients had higher-risk 
lesions and should undergo surgical resection.[3, 4] The risk of progression of residual disease or 
the development of new IPMN or even ductal adenocarcinoma in the remnant pancreas has been 
recognized. The incidence of recurrent IPMN in the remnant pancreas after resection is reported 
between 5.8% and 14.4% in the literature.[5-13] These figures support ongoing surveillance of 
the remaining pancreas, even if the index IPMN lesion has been removed in its entirety. 
 Because of the approximately 60% risk of progression to malignant disease,[4] the 
presence of Main-Duct Involved IPMN (MD-IPMN: Main-Duct or Mixed-Type IPMN) in the 
remnant pancreas warrants further resection. The diagnosis of MD-IPMN is often made by 
unexplained dilation of the main pancreatic duct (MPD), abrupt changes in MPD caliber with 
distal gland atrophy, or through endoscopic ultrasound (EUS) examining for thickened walls or 
intraductal mucin suggestive of MPD involvement.[4] However, the distal pancreatic remnant 
(DPR) after proximal-pancreatectomy (PP) poses a unique and important diagnostic dilemma. In 
the setting of a pancreato-enteric anastomosis, a dilated MPD cannot automatically be interpreted 
as MD-IPMN. In these cases, the presence of a dilated MPD holds a much broader differential 
diagnosis. 
 A dilated MPD after PP may reflect MD-IPMN, anastomotic stricture or ductal 
obstruction with upstream MPD dilation, pancreatitis with gland atrophy, the natural history of 
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the DPR, or a combination thereof.[14-18] Accurate diagnosis in these patients is important, 
because the recommended treatments are vastly different. While MD-IPMN are generally 
resected, alternate diagnoses depending upon the presence and severity of symptoms may be 
treated expectantly, non-operatively or with advanced endoscopic techniques.[16, 19-25] Re-
operation may include anastomotic revision, in which only a small segment of the pancreas is 
removed. In cases with diffuse remnant disease requiring completion pancreatectomy, an 
apancreatic state is created with resulting endocrine and exocrine insufficiency. While surgical 
resection would provide the diagnosis and potentially treat the disease, this must be balanced 
with the known >30% morbidity associated with pancreatic surgery regardless of approach.[26] 
Though endoscopic techniques may provide diagnostic and therapeutic value, because of altered 
post-surgical anatomy, potential structuring, or angulation of the MPD, variable success has been 
reported for both Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and the 
challenging Endoscopic Rendezvous procedure.[19, 22, 27-30] Several prior studies have 
attempted to identify the cross-sectional imaging features of MD-IPMN, pancreatitis, the 
“normal” postoperative pancreas, or anastomotic strictures, but to our knowledge none have 
distinguished between MD-IPMN and other pathologies in the DPR specifically.[31-33]      
 The aim of our study was to evaluate the postoperative diagnostic techniques and 
outcomes for patients who underwent PP for IPMN. We sought to determine which features may 
predict MD-IPMN on DPR re-operative surgical pathology. Our other goal was to better 
understand the natural history of the DPR with/without a dilated MPD after PP for IPMN, and 
better manage those with MPD dilation in an evidence-based manner. 
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METHODS 
Study Population Criteria 
We retrospectively reviewed a prospectively maintained database of 537 patients who 
underwent surgical resection for IPMN between 1991 and 2016 at Indiana University. Patients 
who had undergone either pancreatoduodenectomy (PD) or central pancreatectomy (CP) 
resulting in a left (distal) pancreatic remnant (DPR) with a pancreato-enteric (gastric or jejunal) 
anastomosis were eligible. We refer to either PD or CP as “proximal-pancreatectomy” (PP). 
Patients without available cross-sectional imaging/endoscopy reports postoperatively were 
excluded. Cross-sectional imaging (n=1,172), endoscopic (n=111), DNA profiling (n=32), 
clinical and surgical pathology reports were reviewed. Data were gathered and recorded in 
accordance with the Indiana University Institutional Review Board guidelines. 
For those who underwent re-operation of the DPR, the primary outcome was MD-IPMN 
on surgical pathology. For those undergoing only surveillance after PP, the primary outcome was 
defined as overall benign or malignant.  A malignant outcome was determined by recurrent, 
invasive mass lesion, peritoneal carcinomatosis, or metastatic disease on cross-sectional imaging, 
or cytology/biopsy revealing malignancy.  
We compared groups using the Student’s T/Mann-Whitney U-test for continuous 
variables depending on normality of data, and the Chi-Square/Fisher’s Exact test for categorical 
variables. Proportions, mean and standard error of the mean (SEM), median and range were 
calculated when appropriate. An α-level of 0.05 was considered statistically significant.  IBM-
SPSS software, version 24 was used. 
Variable Definitions 
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1) MPD Dilation: measurement ≥5mm on cross-sectional imaging or endoscopy, or MPD 
described as “dilated;” those only “mildly dilated/mildly prominent” were not included 
2) Surgeon’s Suspicion for MD-IPMN: surgeon noted concern for MD-IPMN as a reason 
for reoperation in preoperative documentation 
3) Endoscopist’s Suspicion for MD-IPMN: gastroenterologist noted concern for MD-IPMN 
in the endoscopy report 
4) Exocrine Insufficiency: documentation of steatorrhea/diarrhea, or prescription of 
pancreatic digestive enzymes 
5) Weight Loss: patient-reported unintended weight loss (any magnitude) post-PP 
6) DNA Parameters: High Quantity DNA (any value other than “Low” Quantity DNA); 
High Quality DNA (any value other than “Poor” Quality DNA); KRAS/GNAS mutation; 
Allelic loss of heterozygosity (LOH) of tumor suppressor genes on MPD fluid aspirates  
7) Positive Margin at PP: includes side-branch/main-duct margins positive for IPMN or 
PanIN, all grades. PanIN falls on a similar spectrum of neoplastic lesions as IPMN. 
Often, the distinction between the two pathologies is dependent on size of the lesion: this 
would be difficult to assess at a surgical margin.  In order to be most inclusive of all 
possible residual IPMN at the PP margin, we included PanIN in this definition.  
Our Institutional Surveillance Protocol 
 After initial evaluation and establishment of a diagnosis of likely IPMN, follow-up is 
individualized based on a number of factors. These include worsening of symptoms, trends in 
laboratory values to suggest pancreatic insufficiency/inflammation (Hemoglobin A1c, c-peptide, 
amylase/lipase), CA19-9 trends, evolution of lesions on radiographic imaging or endoscopy, or 
concerning features on cyst fluid analysis (cytology and molecular profiling).  After an initial 3-4 
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week postoperative visit, similar criteria are considered to guide surveillance after proximal 
pancreatectomy or DPR re-operation. In general, patients are followed every 6-12 months (or in 
rare instances at a 3-month interval) with history and physical exam, radiographic imaging, and a 
panel of laboratory tests (Hemoglobin A1c, c-peptide, CEA, CA19-9, Alkaline Phosphatase, 
Bilirubin, Amylase, Lipase).  Patients with a persistently dilated pancreatic duct ≥4mm that is 
not steadily decreasing in size are followed every 6 months. Depending on stratification to a 
high- or low-risk protocol, patients are generally recommended for endoscopic evaluation every 
3-5 years. 
RESULTS 
A total of 537 patients underwent surgical resection for IPMN between September 1991 
and September 2016. Of these, 317 had undergone PP (PD: n=306, 56.9%; CP: n=11, 2%). 
Seventy-two patients (1 from DPR re-operative group, 71 from DPR surveillance-only group) 
were excluded due to lack of available diagnostic studies during surveillance or prior to re-
operation of the DPR. Most (n=224, 91.4%) of the remaining 245 patients underwent DPR 
surveillance without re-operation. The other 21 patients (8.6%) underwent subsequent DPR 
resection (anastomotic revision or completion pancreatectomy). Based on pre-operative 
documentation, the indications for DPR resection were as follows: concern for PJ stricture ± 
symptoms (n=5), concern for MD-IPMN ± symptoms (n=11), concern for MD-IPMN OR PJ 
stricture (i.e. both mentioned) (n=3), symptoms without presumed etiology provided (n=2). 
DPR Surveillance Cohort 
Of the 224 patients in the DPR surveillance cohort, at the time of PP, 90 (40.2%) patients 
had High-Grade Dysplasia (HGD) or Invasive disease; 120 (53.6%) patients had MD-IPMN, and 
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55 (24.6%) patients had any positive margins (PanIN or IPMN of any grade) on pathology. Only 
3 of these were HGD-IPMN (n=2) or Invasive-IPMN (n=1), which were up-graded on 
permanent pathology from indeterminate/unclear or only “suspicious” frozen section diagnoses. 
Neither the presence of any positive margin, nor HGD/Invasive-IPMN at the margin specifically, 
were associated with a malignant outcome (P>0.05). Seventy-one patients (31.7%) had a dilated 
MPD during surveillance, with a median time to first dilated duct at 365 days (5-3651 days) and 
maximum duct diameter at 432 days (7-3651 days). The median maximum diameter for those 
with a dilated MPD was 6mm (5-13mm).   
A total of 24 (10.7%) patients were determined to have a malignant outcome during DPR 
surveillance, with a median time to diagnosis of 203 days (28-2031 days). Of the 200 (89.3%) 
patients with a benign outcome, the median benign surveillance period was 980 days (4-7246 
days). Of these patients, 153 (76.5%) were followed for ≥1 year, and 122 (61.0%) for ≥2 years. 
When examining clinical, radiographic, and endoscopic factors, only a history of HGD/Invasive 
pathology on PP and CA19-9 levels during DPR surveillance were significantly associated with 
a malignant outcome. (Table 1) Of note, due to occasional missing retrospective data, or certain 
variables only pertinent to patients with a dilated MPD, the denominators throughout Table 1 are 
inconsistent.  Please see the table footnote for further clarification of the data presented. 
Twenty-four of the 24 (100%) patients with a malignant outcome had HGD (1 of 24; 
4.2%) or Invasive (23 of 24; 95.8%) pathology at the time of PP. None of 126 patients (0.0%) 
with Low/Moderate grade IPMN at the time of PP were found to have a malignant outcome at 
most recent surveillance. This association between HGD/Invasive lesions at PP and a malignant 
outcome during DPR surveillance was highly significant (P<0.001). In contrast, 66 of the 200 
patients (33.0%) with a benign outcome had HGD (34 of 200; 17.0%) or Invasive (32 of 200; 
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16.0%) disease at the time of PP. Figure 1 depicts the proportion of benign versus malignant 
outcomes by PP-pathologic grade. For patients with prior Low/Moderate IPMN, the median 
benign surveillance period was 1,010 days (6-6,460 days). The patient with prior HGD-IPMN 
with a malignant outcome was diagnosed much earlier (601 days) compared to those with a 
benign surveillance period of 1,379 days (4-4,549 days). Overall, follow-up was shorter for 
patients with prior Invasive lesions, with median times to malignant (191 days; 28-2,031 days) 
and benign (289 days; 7-3,246 days) outcome diagnoses. These follow-up data are summarized 
in Figure 2.  
During DPR surveillance, patients with malignant outcomes had significantly greater 
maximum CA19-9 levels (669 U/mL; 3-67,107 U/mL) compared to patients with benign 
surveillance (23 U/mL; 1-81,954 U/mL) (P<0.001). However, there was overlap in their ranges. 
Similarly, the patient’s most recent CA19-9 level was greater for patients with a malignant 
outcome (556 U/mL; 3-67,107 U/mL) compared to those with overall benign follow-up (18 
U/mL; 1-81,954 U/mL) (P<0.001).  No other factors were predictive of a malignant outcome. 
Namely, no variables involving MPD dilation or timing of MPD diameter fluctuations predicted 
a malignant outcome during surveillance of the DPR. The variables examined are compared 
between benign and malignant outcome groups in Table 1. Only a small number of patients in 
the DPR-Surveillance group underwent endoscopic MPD fluid aspiration analysis, making 
meaningful interpretation in the present study difficult. Only one patient had concerning 
cytology which proved to be recurrent carcinoma. These data are summarized in Supplemental 
Table 1a.   
DPR Re-Operative Cohort 
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Twenty-one patients were included in the DPR re-operative cohort. On PP pathology, 7 
(33.3%) patients had HGD/Invasive disease; 12 (57.1%) patients had MD-IPMN, and 4 (19.0%) 
had positive margins (all Low/Moderate-IPMN or PanIN 1-2). Nearly all (20 of 21; 95.2%) 
patients had a dilated MPD duct at some point between PP and DPR re-operation. The median 
time to the first dilated MPD was 374 days (8-2651 days) whereas the median time to the 
maximum MPD diameter was 624 days (112-2993 days). Of patients with a dilated MPD in the 
DPR, the median maximum diameter was 7mm (5-16mm).  
Seven of the 21 patients (33.3%) that underwent DPR surgery had MD-IPMN on DPR 
pathology (6 Low/Moderate-IPMN, 1 Invasive-IPMN). These patients underwent DPR surgery a 
median time of 1772 days (148-3815 days) post-PP, which was later than those who underwent 
DPR surgery and had other diagnoses, at 1296 days (450-4928 days). Other diagnoses on DPR 
pathology included Low/Moderate-Grade Side-Branch IPMN with Pancreatitis (n=5), 
Pancreatitis (n=7), Duct Ectasia with Gland Atrophy (n=1) and Small Intestine Adenocarcinoma 
with Pancreatitis (n=1).  
All patients with MD-IPMN on DPR pathology had a dilated MPD at some point post-PP 
(7 of 7, 100.0%). Of all clinical, radiographic, and endoscopic features considered, the maximum 
MPD diameter between PP and DPR surgery was the strongest predictor of MD-IPMN in the 
DPR. Patients with MD-IPMN had a mean maximum MPD diameter of 9.5mm (SEM 1.5mm) 
compared to only 6.2mm (SEM 0.5mm) for those with other diagnoses (P=0.072). Likely due to 
small sample size, this missed reaching statistical significance. The median time to maximum 
duct diameter was 618 days (112-2993 days) for those with MD-IPMN compared to 801 days 
(187-2740) for those with other diagnoses (P=1).  
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Receiver operating characteristic (ROC) curve analysis was performed, and a maximum 
MPD diameter cutoff of 6.5mm provided 85.7% sensitivity and 69.2% specificity for MD-IPMN 
in the DPR, with an area under the curve of 0.780. (Figure 3)  One in 10 (10%) patients with 
maximum MPD diameter before DPR <6.5mm had MD-IPMN on DPR pathology, whereas 6 of 
10 (60%) patients with a maximum MPD diameter ≥6.5mm had MD-IPMN on DPR pathology. 
One patient had a MPD described as “dilated” without a specific measurement, thus were 
excluded from this analysis.  
Several features were highly specific for MD-IPMN in the DPR. A high suspicion for 
MD-IPMN noted by the endoscopist was 83.3% specific for MD-IPMN with PPV of 60.0%, but 
lacked sensitivity (42.9%). On MPD fluid aspirate, the presence of HGD or carcinoma on 
cytology, High Quality DNA, KRAS/GNAS mutation, or allelic LOH provided >80% specificity 
for MD-IPMN, but often lower sensitivity (0.0%-66.7%), as many duct fluid aspirates do not 
display these features. These were examined in only a small number of patients (n=6-13). 
(Supplemental Table 1b) The presence of a normal ductogram (i.e. normal contrast flow 
through the pancreato-enteric anastomosis) was 87.5% specific for MD-IPMN, but poorly 
sensitive at only 33.3%. Thus, most individuals with other diagnoses will display an abnormal 
ductogram. The most sensitive features associated with MD-IPMN were the presence of exocrine 
insufficiency and High Quantity DNA on MPD fluid aspirate, occurring in 100% of cases. The 
surgeon expressed concern for MD-IPMN at the time of DPR re-operation in 71.4% of cases 
revealing MD-IPMN on DPR pathology. None of these highly sensitive features were specific 
for MD-IPMN. Though sensitive or specific, these variables did not reveal statistically 
significant associations with MD-IPMN on DPR surgical pathology (P>0.05). These features are 
summarized in Table 2. Similar to our analysis of the DPR surveillance cohort, the denominators 
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throughout Table 2 and Supplemental Table 1 may change depending on availability of 
retrospective data, certain variables only pertinent to patients with a dilated MPD, or certain 
procedures (endoscopy with pancreatic fluid analysis) only performed on a subset of patients. 
This is further clarified in the table footnote. Based on these data and our institution’s practice, 
we proposed an algorithm for management of the DPR in the setting of a dilated MPD. (Figure 
4) 
DISCUSSION 
 The fate of the pancreatic remnant after resection for IPMN has been examined a number 
of ways. Several prior studies have determined that the rate of metachronous IPMN in any 
remnant pancreas is not negligible, between 5.8% and 14.4%.[5-13] The concern with IPMN is a 
potential for progression to invasive cancer. Miller et al. reported that 2% of individuals who 
underwent resection for non-invasive IPMN went on to develop invasive cancer in the remnant 
pancreas.[34] In a report from Moriya and Traverso, a similarly low rate (2 of 203 patients; 1%) 
of invasive cancer in the remnant pancreas was noted; both of these patients had a prior history 
of HGD/Invasive disease.[9] In a study of the remnant pancreas after initial resection for MD-
IPMN specifically, the rate of recurrence in the form of metastases (11%) or HGD/Invasive 
lesions in the pancreatic remnant (13%) was much greater than other reports;[6] this difference 
may underline the more aggressive nature of MD-IPMN. Because of the higher rate of 
progression to HGD/Invasive disease, the detection of MD-IPMN in the remnant is of upmost 
importance. These prior studies examined the pancreatic remnant in general but not the unique 
dilemma presented by the DPR after PP. While a dilated MPD generally suggests MD-IPMN, in 
the setting of a DPR with a pancreato-enteric anastomosis, the range of possible diagnoses is 
broad. To our knowledge, the present study is the first comprehensive evaluation of the DPR 
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after PP, examining the radiographic, clinical, and endoscopic techniques utilized to predict the 
occurrence of MD-IPMN and malignant outcomes in this specific population.  
 We examined the DPR natural history for 245 patients that initially underwent PP for 
IPMN and found a dilated MPD to be common (37.1% of the entire cohort). Many of the 224 
patients undergoing only DPR surveillance (n=71; 31.7%) had a dilated MPD at some point, 
with a median time to first dilation of 365 days; furthermore, the median maximum diameter of 
the MPD during surveillance was 6mm at a median time of 432 days after PP. Because these 
individuals did not undergo re-operative surgery, we were unable to determine if this MPD 
dilation represented MD-IPMN or an alternate diagnosis. However, the presence of a dilated 
MPD during surveillance of the DPR, the maximum diameter of the MPD during surveillance, 
and the timing of these fluctuations did not predict a malignant outcome. In contrast to the 
International Consensus Guidelines recommendations for surgical resection of patients with 
dilated MPD in a pre-operative pancreas,[4] in the setting of a dilated MPD in the DPR after PP, 
our findings do not support automatic surgical resection to prevent a malignant outcome.  
The strongest predictor of a malignant outcome was the presence of HGD/Invasive 
disease at PP, with median time to malignant outcome of 203 days (75% of individuals 
diagnosed within 632 days). Thus, most patients with a history of HGD/Invasive disease will 
present with a recurrence or progression of their malignancy within 2 years of PP. The majority 
(66 of 90; 73.3%) of patients with HGD/Invasive disease ultimately had a benign outcome at 
most recent surveillance, at a median time of 834 days, including those with a dilated MPD 
(n=21; 31.8%). These findings support rigorous surveillance for evidence of malignant 
progression, especially in the years immediately following PP, for patients with a history of 
HGD/Invasive disease regardless of MPD diameter. In our cohort, no individuals with 
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Low/Moderate-Grade IPMN at the time of PP went on to develop evidence of malignancy during 
DPR surveillance, with a median follow-up period of 1010 days. These data may support 
ongoing surveillance and diagnostic evaluation of patients with a history of Low/Moderate-
Grade disease, even in the presence of a dilated MPD (n=45; 35.7%) over immediate surgical 
resection.  
The other factor predicting a malignant outcome in the present study was a greater CA19-
9 level, both maximum and most recent values after PP. While this association between greater 
CA 19-9 level and increasing grade of IPMN has been demonstrated in the literature,[35, 36] 
others have not validated this relationship.[37] In a prior study by Park et al., an elevated CA 19-
9 level preceding surgery was found to be associated with disease recurrence after resection of 
IPMN; 12 of 13 recurrent cases had invasive disease at the time of index operation, and 10 of the 
13 patients had recurrence outside of the remnant pancreas suggesting advanced, metastatic 
disease.[13] This prior report approximates our findings and the relationship between prior 
HGD/Invasive pathology, elevated CA 19-9 level, and malignant outcomes. However, in contrast 
to the pre-operative CA 19-9 levels described in these prior studies, the CA 19-9 levels described 
in the present study are reflective of the post-PP surveillance of the DPR.  
In the DPR re-operative cohort, only 2 individuals had aggressive lesions (1 small bowel 
adenocarcinoma, 1 invasive-IPMN). While it may be argued that only 2 patients benefitted from 
DPR resection, the benefit of symptomatic relief and clarification of pathology (MD-IPMN vs 
alternate diagnoses) to better guide management cannot be ignored. Once we are able to reliably 
establish a diagnosis of MD-IPMN in the DPR, efforts focused on isolating only the highest-risk 
lesions (HGD/Invasive-IPMN) should be undertaken. Because one of the most reliable features 
of the International Consensus Guidelines, MPD diameter, is confounded in this post-PP 
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population, the future of diagnosing HGD/Invasive-IPMN in this population will likely rely on 
more individualized assessment through cyst fluid/serum molecular profiling or biomarker 
analyses. The present study has limited molecular data available on a small number of patients 
and should be the focus of future studies.      
While predicting which individuals will have a malignant outcome after resection of 
IPMN is difficult, determining which patients have a MD-IPMN in the setting of a DPR after PP 
is the first challenge in order to resect and potentially prevent progression to malignant disease. 
Conventional diagnostics including cross-sectional imaging and endoscopy are complicated by 
the altered foregut anatomy and pancreato-enteric anastomosis of a post-PP pancreas. For the 
pre-operative pancreas, the MPD diameter is of upmost importance in guiding resection of likely 
MD-IPMN in the International Consensus Guidelines. In the present study, all MD-IPMN 
diagnosed in the DPR had a maximum MPD diameter of at least 5mm; 6 of the 7 (85.7%) 
patients with DPR MD-IPMN had a maximum MPD diameter of ≥7mm. This range corresponds 
with the minimum MPD diameter of 5mm (considered a Worrisome Feature) to 
diagnose/evaluate for MD-IPMN by the 2012 International Consensus Guidelines.[4] In general, 
patients with MD-IPMN in the DPR had a greater maximum MPD diameter, with shorter time to 
maximum MPD diameter, compared to those with other diagnoses, but these findings did not 
reach statistical significance. Crippa et al. also reported a greater median MPD diameter for 
those with MD-IPMN compared to other diagnoses, though this prior study was of the pre-
operative pancreas rather than the DPR.[38] We determined that with a maximum MPD cutoff of 
6.5mm, the sensitivity (85.7%) and specificity (69.2%) for MD-IPMN in the DPR were 
optimized. Based on these findings, patients with a maximum MPD <6.5mm in the DPR are 
unlikely to have MD-IPMN (only 1 of 10 patients), while 6 of 10 (60%) of patients with a 
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maximum dilated MPD ≥6.5mm harbored MD-IPMN. These individuals particularly require 
further evaluation.   
Advanced endoscopic techniques including endoscopic ultrasound (EUS) with or without 
fine needle aspiration (FNA) of cyst/duct fluid, or ERCP are performed to fully examine 
pancreatic lesions, gather biopsies, or treat obstructive pathology. While this can be a challenge 
in the post-PP patient, our data suggest that the information gathered from these diagnostic 
techniques are valuable for determining DPR pathology. In the present study, endoscopic 
evaluation by the gastroenterologist led to greater specificity, accuracy, and positive-predictive 
value for predicting MD-IPMN compared to the surgeon’s suspicion. In our series, the 
gastroenterologist was more skilled at “ruling-in” MD-IPMN, which may help to reduce 
unnecessary surgical resection for non-neoplastic disease that may be managed non-operatively.  
Features of MPD fluid aspirates gathered through EUS-FNA proved to be either highly 
sensitive or specific for MD-IPMN. The most specific DNA factors with the greatest positive-
predictive value for MD-IPMN in the DPR included High Quality DNA, GNAS mutation, or 
allelic LOH. This is in accordance with prior reports, whereas High Quality DNA and LOH were 
associated with mucinous cysts [39, 40] and GNAS mutation predicted IPMN specifically.[41, 
42] The most sensitive MPD aspirate features for MD-IPMN in the DPR were the presence of 
mucin (80.0%) or High Quantity DNA (100.0%). Because IPMN represent a neoplastic process 
characterized by mucin production, it follows that most patients with MD-IPMN would reveal 
mucin in the MPD upon aspiration. In a prior study by Morris-Stiff et al. mucin on cyst fluid 
aspirate was similarly found to be highly sensitive (80%) but poorly specific (40%) for mucinous 
lesions.[43] The presence of High Quantity DNA on MPD fluid aspirate was highly sensitive 
(100.0%) for MD-IPMN, but poorly specific (40.0%). This is mechanistically reasonable. With a 
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neoplastic process there may be greater cell turnover and DNA shedding into the cyst/ductal 
fluid. However, benign inflammatory processes, may also release cellular DNA into the cyst or 
ductal fluid.[44]   
 To fully visualize the pancreatic and biliary ductal system, ERCP may be employed. But 
in cases where ERCP is unsuccessful, the gastroenterologist may perform EUS-guided pancreatic 
ductography to gain access to and visualize the MPD.[45] With contrast injection into the MPD, 
in the present study, a ductogram revealing normal flow into the bowel (i.e. no anastomotic 
stricture or obstruction) was highly specific for MD-IPMN over an alternate diagnosis.  
In general, clinical symptoms were not helpful in diagnosing MD-IPMN in the DPR. 
100.0% of patients with MD-IPMN were noted to have exocrine insufficiency or be treated with 
pancreatic enzyme supplementation; however, because of the liberal use of pancreatic enzymes 
in the postoperative period for PP patients at our institution, this result is not surprising. 
Similarly, while abdominal pain was highly sensitive for MD-IPMN in the DPR (85.7%), this 
was poorly specific, as many patients with alternate diagnoses (i.e. stricture or pancreatitis) also 
reported abdominal pain during DPR surveillance. The most specific (71.4%) clinical indicator 
of MD-IPMN in the DPR was patient-reported unexplained weight loss, occurring twice as 
frequently in those with MD-IPMN (57.1%) compared to those with other diagnoses in the DPR 
(28.6%). While MD-IPMN, mucin, pancreatitis, or stricture of the pancreato-enteric anastomosis 
may all contribute to ductal obstruction, exocrine insufficiency, and ultimately weight loss,[46] it 
is unclear why this feature was reportedly more prominent in those with MD-IPMN in the 
present study. The surgeon was concerned about MD-IPMN in most cases, leading to high 
sensitivity but poor specificity for MD-IPMN in the DPR. This highlights the need for deliberate 
diagnostic evaluation often via endoscopy—and attempts at non-operative mitigation of any 
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obstructive symptoms—as automatically operating based on the surgeon’s suspicion for MD-
IPMN alone would lead to a large number of unnecessary surgeries for non-neoplastic disease (9 
of 14 non MD-IPMN cases; 64.3%).  
Our study is limited by the nature of a retrospective data review. As some diagnostic 
studies did not have an actual MPD measurement, but were rather described as “dilated,” “mildly 
dilated,” or “mildly prominent,” this variable was operationalized to avoid excluding data. The 
crux of this study is the diagnostic challenge of determining the presence of MD-IPMN in the 
DPR. As such, without surgical pathology, it was impossible to definitively determine the 
etiology of a dilated MPD in our surveillance cohort. Instead, we determined if these individuals 
had a benign or malignant outcome at follow-up. While some individuals in the benign group 
may still develop a metachronous malignancy in the future, we feel that the overall surveillance 
period for those determined to have a benign outcome was sufficient to allow time for this to 
occur. Many of our variables of interest did not reach statistical significance, likely due to an 
overall underpowered study with only 21 individuals undergoing re-operative DPR surgery, and 
only 24 malignant outcomes in the DPR surveillance cohort. Similarly, for a number of our 
analyses, very few patient samples were available for inclusion (i.e. MPD fluid aspirates). As 
such, this data should be interpreted cautiously. Future larger studies are necessary to validate 
our findings, determine statistically significant relationships, and add to the paucity of 
knowledge on this subject. 
CONCLUSION 
 Dilation of the MPD in the DPR after PP is a common finding. The diagnostic dilemma 
stands in determining if this MPD dilation represents MD-IPMN, which requires surgical 
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resection, versus an alternate diagnosis that may be managed non-operatively. While MPD 
dilation did not predict a malignant outcome, there is some evidence to suggest that the 
maximum diameter reached in the DPR may be slightly greater for MD-IPMN over other 
diagnoses. When the maximum MPD diameter is <6.5mm, the rate of MD-IPMN in the DPR 
was only 10% compared to 60.0% for those with a maximum MPD diameter of 6.5mm or 
greater. Because the surgeon’s suspicion alone did not prove to be highly specific for MD-IPMN 
in the DPR, the use of endoscopy with MPD fluid aspirate analysis and EUS-guided pancreatic 
ductography is supported to assist with more accurate diagnosis. 
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TABLES 
Table 1. Characteristics of Patients with Malignant (n=24) Versus Benign (n=200) 
Outcomes During Surveillance of the Distal Pancreatic Remnant 
 
 
 
 
 
 
 
 
Malignant Benign P-value Sn Sp Acc PPV NPV
High Grade/Invasive Pathology 24/24 (100%) 66/192 (34.4%) <0.001 100.0% 65.6% 69.4% 26.7% 100.0%
Invasive Pathology 23/24 (95.8%) 32/192 (16.7%) <0.001 95.8% 83.3% 84.7% 41.8% 99.4%
MD-IPMN 11/17 (64.7%) 109/198 (55.1%) 0.442 64.7% 44.9% 46.5% 9.2% 93.7%
Positive Margin 8/24 (33.3%) 47/200 (23.5%) 0.290 33.3% 76.5% 71.9% 14.5% 90.5%
*Time to 1st Dilated Duct (days) 277 (57-2031) 370 (5-3651) 0.905  -  -  -  -  - 
*Time to 1st Dilated Duct if Normal pre-PP (days) 1215 (277-2031) 525.5 (7-3651) 0.635  -  -  -  -  - 
*MPD Maximum Diameter (mm) 5 (5-5) 6 (5-13) 0.386  -  -  -  -  - 
*Time to Maximum Dilated Duct (days) 277 (277-277) 455.5 (7-3651) 0.456  -  -  -  -  - 
Dilated Remnant Duct 5/24 (20.8%) 66/200 (33.0%) 0.226 20.8% 67.0% 62.1% 7.0% 87.6%
*Dilation Decreasing from Maximum to Most Recent 3/5 (60.0%) 42/60 (70.0%) 0.639 60.0% 30.0% 32.3% 6.7% 90.0%
*Dilation Resolved from Maximum to Most Recent 2/3 (66.7%) 31/59 (52.5%) 1.000 66.7% 47.5% 48.4% 6.1% 96.6%
Maximum Surveillance CA 19-9 (U/mL) 669 (3-67107) 23 (1-81954) <0.001  -  -  -  -  - 
Most Recent Surveillance CA 19-9 (U/mL) 556 (3-67107) 18 (1-81954) <0.001  -  -  -  -  - 
Uptrending CA 19-9 8/22 (36.4%) 35/112 (31.25%) 0.639 36.4% 68.8% 63.4% 18.6% 84.6%
* indicates  this  feature i s  only pertinent to patients  with a  di lated main pancreatic duct (mal ignant n=5, benign n=66)
Proximal Pancreatectomy Variables
Post Proximal-Pancreatectomy Radiographic Variables
Categorica l  variables  expressed as  N-pos i tive/N-tested (%); Continuous  variables  with normal  dis tribution expressed as  mean (s tandard error of the mean); 
Continuous  variables  with non-normal  dis tribution expressed as  median (range); MPD  Main Pancreatic Duct
Post Proximal-Pancreatectomy Clinical Variables
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Table 2. Characteristics of Patients with MD-IPMN (n=7) or No MD-IPMN (n=14) on Re-
Operative Surgical Pathology of the Distal Pancreatic Remnant 
 
 
 
 
 
MD-IPMN No MD-IPMN P-value Sn Sp Acc PPV NPV
MPD Diameter Pre-Op (mm) 6 (2-12) 4 (1.6-15) 0.503  -  -  -  -  - 
Dilated Duct Pre-Op 4/6 (66.7%) 5/13 (38.5%) 0.350 66.7% 61.5% 63.2% 44.4% 80.0%
High Grade/Invasive Pathology 2/7 (28.6%) 5/13 (38.5%) 1.000 28.6% 61.5% 50.0% 28.6% 61.5%
Invasive Pathology 2/7 (28.6%) 1/13 (7.7%) 0.270 28.6% 92.3% 70.0% 66.7% 70.6%
MD-IPMN 4/7 (57.1%) 8/14 (57.1%) 1.000 57.1% 42.9% 47.6% 33.3% 66.7%
Positive Margin 2/6 (33.3%) 2/14 (14.3%) 0.549 33.3% 85.7% 70.0% 50.0% 75.0%
*Time to 1st Dilated Duct Pre-Op (days) 341 (96-2651) 398 (8-981) 1.000  -  -  -  -  - 
MPD Maximum Diameter Pre-Op (mm) 9.5 (1.5) 6.2 (0.5) 0.072  -  -  -  -  - 
Time to Maximum Diameter Pre-Op (days) 618 (112-2993) 801 (187-2740) 1.000  -  -  -  -  - 
MPD Diameter Immediately Pre-Op (mm) 7.4 (1.8) 5.6 (0.5) 0.355  -  -  -  -  - 
Dilated Duct Pre-Op 7/7 (100%) 13/14 (92.9%) 1.000 100.0% 7.1% 38.1% 35.0% 100.0%
*Dilation Decreased from Maximum to PreOp 4/7 (57.1%) 5/13 (38.5%) 0.642 57.1% 61.5% 60.0% 44.4% 72.7%
*Dilation Resolves from Maximum to Preop 2/7 (28.6%) 2/13 (15.4%) 0.587 28.6% 84.6% 65.0% 50.0% 68.8%
*Good Secretin Response on MRCP 2/3 (66.7%) 6/12 (50.0%) 1.000 66.7% 50.0% 53.3% 25.0% 85.7%
Endoscopist Suggests MD-IPMN 3/7 (42.9%) 2/12 (16.7%) 0.305 42.9% 83.3% 68.4% 60.0% 71.4%
Endoscopy Not Suggestive of Stricture 5/7 (71.4%) 5/12 (41.7%) 0.350 71.4% 58.3% 63.2% 50.0% 77.8%
Normal Ductogram 1/3 (33.3%) 1/8 (12.5%) 0.491 33.3% 87.5% 72.7% 50.0% 77.8%
Pre-DPR Re-Operation CA 19-9 (U/mL) 30 (6-237) 23 (3-4722) 0.913  -  -  -  -  - 
Any Symptoms 7/7 (100.0%) 13/14 (92.9%) 1.000 100.0% 7.1% 38.1% 35.0% 100.0%
Pancreatitis 4/7 (57.1%) 9/14 (64.3%) 1.000 57.1% 35.7% 42.9% 30.8% 62.5%
Exocrine Insufficiency 7/7 (100.0%) 9/14 (64.3%) 0.123 100.0% 35.7% 57.1% 43.8% 100.0%
Abdominal Pain 6/7 (85.7%) 10/14 (71.4%) 0.624 85.7% 28.6% 47.6% 37.5% 80.0%
Weight Loss 4/7 (57.1%) 4/14 (28.6%) 0.346 57.1% 71.4% 66.7% 50.0% 76.9%
Surgeon's Concern for MD-IPMN 5/7 (71.4%) 9/14 (64.3%) 1.000 71.4% 35.7% 47.6% 35.7% 71.4%
Uptrending CA 19-9 4/6 (66.7%) 7/11 (63.6%) 1.000 66.7% 36.4% 47.1% 36.4% 66.7%
* indicates  this  feature i s  only pertinent to patients  with a  di lated main pancreatic duct (MD-IPMN n=7, Non MD-IPMN n=13)
Pre-Distal Remnant Resection Clinical Variables
Categorica l  variables  expressed as  N-pos i tive/N-tested (%); Continuous  variables  with normal  dis tribution expressed as  mean (s tandard error of 
the mean); Continuous  variables  with non-normal  dis tribution expressed as  median (range); MPD  Main Pancreatic Duct
Proximal Pancreatectomy Variables
Pre-Distal Remnant Resection Radiographic Variables
Pre-Distal Remnant Resection Endoscopic Variables
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Supplemental Table 1. Pancreatic Duct Fluid Analysis for Patients With a) Malignant 
(n=24) Versus Benign (n=200) Outcomes During Surveillance of the Distal Pancreatic 
Remnant and b) Patients with MD-IPMN (n=7) or No MD-IPMN (n=14) on Re-Operative 
Surgical Pathology of the Distal Pancreatic Remnant 
 
 
 
 
 
 
Malignant Benign P-value Sn Sp Acc PPV NPV
MPD Aspirate CEA (ng/mL)  - 167 (0.3-12120)  -  -  -  -  -  - 
MPD Aspirate CEA > 192 0/0 (0.0%) 7/14 (50.0%)   -  - 50.0% 50.0% 0.0% 100.0%
MPD Aspirate + Mucin 0/0 (0.0%) 5/14 (27.8%)  -  - 72.2% 72.2% 0.0% 100.0%
MPD Aspirate Cytology (HGD/CA) 1/1 (100.0%) 0/18 (0.0%) 0.053 100.0% 100.0% 100.0% 100.0% 100.0%
MPD Aspirate High Quantity DNA 0/0 (0.0%) 9/12 (75.0%)  -  - 25.0% 25.0% 0.0% 100.0%
MPD Aspirate High Quality DNA 0/0 (0.0%) 4/12 (33.3%)  -  - 66.7% 66.7% 0.0% 100.0%
MPD Aspirate KRAS OR GNAS 0/0 (0.0%) 1/11 (9.1%)  -  - 90.9% 90.9% 0.0% 100.0%
MPD Aspirate KRAS  0/0 (0.0%) 1/11 (9.1%)  -  - 90.9% 90.9% 0.0% 100.0%
MPD Aspirate GNAS 0/0 (0.0%) 0/2 (0.0%)  -  - 100.0% 100.0% 0.0% 100.0%
MPD Aspirate LOH 0/0 (0.0%) 0/7 (0.0%)  -  - 100.0% 100.0% 0.0% 100.0%
MD-IPMN No MD-IPMN P-value Sn Sp Acc PPV NPV
MPD Aspirate CEA (ng/mL) 114 (15-28505) 108 (12-672) 0.786  -  -  -  -  - 
MPD Aspirate CEA > 192 1/3 (33.3%) 2/5 (40.0%) 1.000 33.3% 60.0% 50.0% 33.3% 60.0%
MPD Aspirate + Mucin 4/5 (80.0%) 3/8 (37.5%) 0.266 80.0% 62.5% 69.2% 57.1% 83.3%
MPD Aspirate Cytology (HGD/CA) 1/5 (20.0%) 0/8 (0.0%) 0.385 20.0% 100.0% 69.2% 100.0% 66.7%
MPD Aspirate High Quantity DNA 3/3 (100.0%) 3/5 (60.0%) 0.464 100.0% 40.0% 62.5% 50.0% 100.0%
MPD Aspirate High Quality DNA 2/3 (66.7%) 1/5 (20.0%) 0.464 66.7% 80.0% 75.0% 66.7% 80.0%
MPD Aspirate KRAS OR GNAS 1/3 (33.3%) 0/4 (0.0%) 0.429 33.3% 100.0% 71.4% 100.0% 66.7%
MPD Aspirate KRAS  0/3 (0.0%) 0/4 (0.0%)  - 0.00% 100.0% 57.4%  - 57.1%
MPD Aspirate GNAS 1/2 (50.0%) 0/4 (0.0%) 0.333 50.0% 100.0% 83.3% 100.0% 80.0%
MPD Aspirate LOH 1/3 (33.3%) 0/3 (0.0%) 1.000 33.3% 100.0% 66.7% 100.0% 60.0%
a. Post Proximal-Pancreatectomy Pancreatic Duct Fluid Analysis
Categorica l  variables  expressed as  N-pos i tive/N-tested (%); MPD  Main Pancreatic Duct;  LOH  Loss  of Heterozygos i ty of Tumor Suppressor Genes ; CEA 
Carcinoembryonic Antigen
b. Pre-Distal Remnant Resection Pancreatic Duct Fluid Analysis
Dilemma Dilated MPD Remnant 
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FIGURE LEGENDS 
Figure 1. Overall Surveillance Outcomes by Proximal Pancreatectomy Surgical Pathology 
Figure 2. Median Time to Outcome Determination by Proximal Pancreatectomy Surgical 
Pathology 
Figure 3. Receiver Operating Characteristic Curve for Maximum Main Pancreatic Duct 
Diameter in the Distal Pancreatic Remnant and MD-IPMN on Distal Pancreatic Remnant 
Surgical Pathology 
Figure 4. Proposed Management Algorithm for the Distal Pancreatic Remnant 
 
 
 
 
 
 
 
 
 
 
Dilemma Dilated MPD Remnant 
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Figure 2.  
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
Dilemma Dilated MPD Remnant 
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Figure 4. 
 
 
